checkAd

     3835  0 Kommentare Novartis to license Google "smart lens" technology - Seite 3

    About Novartis
    Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.
    Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

    # # #

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Novartis AG!
    Long
    88,98€
    Basispreis
    0,67
    Ask
    × 14,78
    Hebel
    Short
    99,94€
    Basispreis
    0,71
    Ask
    × 13,97
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Novartis Media Relations

    Central media line : +41 61 324 2200
    Eric Althoff
    Novartis Global Media Relations
    +41 61 324 7999 (direct)
    +41 79 593 4202 (mobile)
    eric.althoff@novartis.com
    Elizabeth Harness Murphy
    Alcon Global Media Relations
    +1 817 551 8696 (direct)
    +1 585 435 7379 (mobile)
    Elizabeth.Murphy@alcon.com

    e-mail: media.relations@novartis.com

    For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
    For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.

    Lesen Sie auch

    Novartis Investor Relations

    Central phone: +41 61 324 7944
    Samir Shah +41 61 324 7944 North America:
    Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
    Thomas Hungerbuehler +41 61 324 8425 Susan Donofrio +1 862 778 9257
    Isabella Zinck +41 61 324 7188
    e-mail: investor.relations@novartis.com e-mail: investor.relations@novartis.com




    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Novartis International AG via Globenewswire

    HUG#1824836

    --- End of Message ---

    Novartis International AG
    P.O. Box Basel Switzerland

    WKN: 904278;ISIN: CH0012005267;


    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Novartis to license Google "smart lens" technology - Seite 3 Novartis International AG / Novartis to license Google "smart lens" technology . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Innovative technology offers …

    Schreibe Deinen Kommentar

    Disclaimer